Full Description
Infectious diseases continue to pose a substantial threat to the operational capacity of military forces. Protecting Our Forces reviews the process by which the U.S. military acquires vaccines to protect its warfighters from natural infectious disease threats. The committee found that poorly aligned acquisition processes and an inadequate commitment of financial resources within the Department of Defense vaccine acquisition process ? rather than uncleared scientific or technological hurdles ? contribute to the unavailability of some vaccines that could protect military personnel and, implicitly, the welfare and security of the nation. Protecting Our Forces outlines ways in which DoD might strengthen its acquisition process and improve vaccine availability. Recommendations, which include combining all DoD vaccine acquisition responsibilities under a single DoD authority, cover four broad aspects of the acquisition process: (1) organization, authority, and responsibility; (2) program and budget; (3)manufacturing; (4) and the regulatory status of special-use vaccines.
Table of Contents
Front Matter
Executive Summary
1 Introduction and History
2 Resources, Responsibilities, and Dynamics in the Military's
Vaccine Mission
3 Current Status of Vaccines for Military Personnel
4 Recommendations with Accompanying Analysis of Limitations Imposed
by Current Department of Defense Structure for Managing Acquisition
of Vaccines Against Infectious Diseases
References
Appendix A: Reprint of the commitee's November 2000 Interim Report,
Urgent Attention Needed to Restore Lapsed Adenovirus Vaccine
Availability: A Letter Report,
Appendix B: Open Meeting Agendas
Appendix C: Committee and Staff Biographies
Contents
1 Front Matter; 2 Executive Summary; 3 1 Introduction and History; 4 2 Resources, Responsibilities, and Dynamics in the Military's Vaccine Mission; 5 3 Current Status of Vaccines for Military Personnel; 6 4 Recommendations with Accompanying Analysis of Limitations Imposed by Current Department of Defense Structure for Managing Acquisition of Vaccines Against Infectious Diseases; 7 References; 8 Appendix A: Reprint of the commitee's November 2000 Interim Report, Urgent Attention Needed to Restore Lapsed Adenovirus Vaccine Availability: A Letter Report,; 9 Appendix B: Open Meeting Agendas; 10 Appendix C: Committee and Staff Biographies
